CS Medica (NGM:CSMED) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CSMED Overzicht aandelen

CS MEDICA A/S ontwikkelt, produceert en verkoopt vrij verkrijgbare medische producten die cannabinoïden bevatten voor de behandeling van psoriasis en artritis.

Over het bedrijf

CSMED fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Has less than 1 year of cash runway

Earnings have declined by 50.2% per year over past 5 years

Makes less than USD$1m in revenue (DKK5M)

Highly volatile share price over the past 3 months

+ 1 meer risico

CS Medica A/S Concurrenten

AcuCort

NGM:ACUC

SEK 113.2m

PEPTONIC medical

NGM:PMED

SEK 92.1m

Corline Biomedical

OM:CLBIO

SEK 177.1m

Double Bond Pharmaceutical International

NGM:DBP B

SEK 40.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor CS Medica
Historische aandelenkoersen
Huidige aandelenkoers	DKK 8.66
52 Week Hoogtepunt	DKK 17.99
52 Week Laag	DKK 3.05
Bèta	-0.96
11 maand verandering	-33.80%
3 maanden verandering	66.93%
1 Jaar Verandering	54.38%
33 jaar verandering	1.04%
5 jaar verandering	n/a
Verandering sinds IPO	-18.66%

Recent nieuws en updates

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Recent updates

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Rendement voor aandeelhouders

	CSMED	SE Pharmaceuticals	SE Markt
7D	-7.4%	1.5%	0.8%
1Y	54.4%	68.2%	25.1%

Rendement versus industrie: CSMED underperformed the Swedish Pharmaceuticals industry which returned 67.6% over the past year.

Rendement versus markt: CSMED exceeded the Swedish Market which returned 24.5% over the past year.

Prijsvolatiliteit

Is CSMED's price volatile compared to industry and market?
CSMED volatility
CSMED Average Weekly Movement	23.7%
Pharmaceuticals Industry Average Movement	11.4%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.6%
10% least volatile stocks in SE Market	3.2%

Stabiele aandelenkoers: CSMED's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: CSMED's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	9	Lone Henriksen	www.cs-medica.com

CS MEDICA A/S ontwikkelt, produceert en verkoopt vrij verkrijgbare medische producten die cannabinoïden bevatten voor de behandeling van psoriasis en artritis. Het biedt gels voor psoriasis, artritis, beschermende neus en wondgenezing; en CBD anti-haaruitval serum, evenals slaap neussprays en pijn pleisters. Het bedrijf biedt zijn producten voornamelijk aan onder de merknaam CANNASEN.

CS Medica A/S Samenvatting

Hoe verhouden de winst en inkomsten van CS Medica zich tot de beurswaarde?
CSMED fundamentele statistieken
Marktkapitalisatie	DKK 69.99m
Inkomsten(TTM)	-DKK 12.31m
Inkomsten(TTM)	DKK 4.67m

22.9x

P/S-verhouding

-8.7x

Koers/Winstverhouding

Is CSMED overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CSMED resultatenrekening (TTM)
Inkomsten	DKK 4.67m
Kosten van inkomsten	DKK 2.85m
Brutowinst	DKK 1.81m
Overige uitgaven	DKK 14.12m
Inkomsten	-DKK 12.31m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 14, 2024

Winst per aandeel (EPS)	-1.00
Brutomarge	38.81%
Nettowinstmarge	-263.84%
Schuld/Eigen Vermogen Verhouding	676.5%

Hoe presteerde CSMED op de lange termijn?

Bekijk historische prestaties en vergelijking

CSMED Overzicht aandelen

Beloningen

Risicoanalyse

CS Medica A/S Concurrenten

NGM:ACUC

SEK 113.2m

NGM:PMED

SEK 92.1m

OM:CLBIO

SEK 177.1m

NGM:DBP B

SEK 40.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

CS Medica A/S to Report Q3, 2024 Results on Jul 31, 2024

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Second quarter 2024 earnings released

Recent updates

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

CS Medica A/S to Report Q3, 2024 Results on Jul 31, 2024

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Second quarter 2024 earnings released

CS Medica A/S to Report Fiscal Year 2024 Results on Nov 28, 2024

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report Q4, 2024 Results on Nov 14, 2024

Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products

New major risk - Share price stability

New major risk - Market cap size

CS Medica A/S to Report Q3, 2023 Results on Aug 08, 2023

CS Medica A/S to Report Q3, 2023 Results on Jul 18, 2023

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

New major risk - Market cap size

CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis

CS Medica A/S to Report Fiscal Year 2022 Final Results on Jan 27, 2023

CS Medica A/S to Report Q1, 2023 Results on Feb 17, 2023

CS Medica A/S, Annual General Meeting, Feb 09, 2023

CS Medica A/S Provides Update on Clinical Trials

Full year 2022 earnings released: kr.0.90 loss per share (vs kr.0.059 profit in FY 2021)

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

CS Medica A/S Provides Revenue Guidance for the Year 2022

CS MEDICA Provides Patent Update

CS Medica A/S to Report Fiscal Year 2022 Results on Nov 18, 2022

CS MEDICA A/S Reports Proof of Concept in the Results from the Clinical Trial on NGP-01 (Cannasen®Cbd Psoriasis Gel) Against Placebo

CS MEDICA A/S Announces Groundbreaking Discovery in the Natural Cannabinoid CBD's Activity in the Body

Cs Medica Announces Positive Clinical Trial Results from the Final Report on Nga-01 Gel & Nsa-01 Capsule in Combination Against Placebo

CS Medica A/S Reports the Results from the Clinical Trial on NGA-01(CANNASEN®CBD Arthritis Gel) Against Placebo

CS MEDICA A/S Provides Revenue Guidance for 2023/2024

No independent directors

CS Medica Receives the Final Approval from Hong Kong Customs, the Drug Registration Office

CS MEDICA A/S Provides Patent Update

CS MEDICA A/S Finalizes THC Test At PPB Level on Their Cannasen®Cbd Products to Comply with the Strict Regulations on the Asian Market

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CS MEDICA A/S Reaffirms Revenue Guidance for the Fiscal Year 2022

CS MEDICA A/S Announces Their CANNANSEN®CBD Anti-Hair Loss Serum Approves in the United Arab Emirates

CS MEDICA A/S Announces an Additional Five Intellectual Property Rights Registrations

No independent directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

CS Medica A/S Samenvatting

22.9x

-8.7x

Inkomsten en omzet